Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.…
CorMedix Inc. Q3 2026 Earnings Call Summary
Heron Therapeutics (NASDAQ: HRTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 128 employees.
The shares were at 0.2525 USD on 20 November 2026, down 77.0% over 52 weeks. Its 52-week range is 0.2479 USD to 1.580 USD: the price is 84.0% below the high and 1.9% above the low.
Its market capitalisation is 48.04M USD.
Heron Therapeutics reports return on equity of -140.9%, an operating margin of -5.7% and revenue down 7.8% year over year.
Its debt exceeds its cash by 108.28M USD, a debt-to-equity ratio of 9.81. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.